Basic Information
Obgemsa
Regulatory Information
EMEA/H/C/005957
Authorised
June 27, 2024
April 25, 2024
1
February 19, 2025
Company Information
PIERRE FABRE MEDICAMENT
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Obgemsa is indicated in symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.
Overview Summary
Obgemsa is a medicine used to treat adults with overactive bladder syndrome (OAB). It is used to treat symptoms of the condition such as urgency (sudden urge to urinate), increased urinary frequency (need to urinate frequently) and urge incontinence (involuntary leakage when a sudden strong need to urinate is felt). Obgemsa contains the active substance vibegron.